# Akero Therapeutics Inc. (AKRO)

Source: https://www.quantisnow.com/company/AKRO
Generated: 2026-11-12T15:44:59.951Z

- Ticker: AKRO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2019
- Website: akerotx.com

## About

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

## Latest AKRO news and filings

- 2026-07-14 10:00 UTC [Conference Announcement] [NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy](https://www.quantisnow.com/insight/nextcure-and-avere-therapeutics-announce-merger-to-advance-once-weekly-oral-6635858)
- 2025-12-19 21:05 UTC [SEC Form 15-12G filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-akero-therapeutics-inc-6323666)
- 2025-12-09 15:40 UTC [SEC Form 25-NSE filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-akero-therapeutics-inc-6308424)
- 2025-12-09 15:26 UTC [SEC Form 4] [Director Heyman Tomas J. returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-heyman-tomas-j-returned-9398-shares-to-the-company-6308415)
- 2025-12-09 15:25 UTC [SEC Form 4] [Director Xu Yuan returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-xu-yuan-returned-9398-shares-to-the-company-closing-6308414)
- 2025-12-09 15:24 UTC [SEC Form 4] [President and CEO Cheng Andrew returned 436,837 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-cheng-andrew-returned-436837-shares-to-the-6308413)
- 2025-12-09 15:21 UTC [SEC Form 4] [Director Harrison Seth Loring returned 293,762 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-harrison-seth-loring-returned-293762-shares-to-the-company-6308410)
- 2025-12-09 15:17 UTC [SEC Form 4] [Director Graham G. Walmsley returned 1,302,398 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-graham-g-walmsley-returned-1302398-shares-to-the-company-6308407)
- 2025-12-09 15:17 UTC [SEC Form 4] [Director Judy Chou returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-judy-chou-returned-9398-shares-to-the-company-closing-6308406)
- 2025-12-09 15:14 UTC [SEC Form 4] [Chief Scientific Officer Rolph Timothy returned 282,149 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-rolph-timothy-returned-282149-shares-to-the-6308405)
- 2025-12-09 15:14 UTC [SEC Form 4] [Director Iwicki Mark T returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-iwicki-mark-t-returned-9398-shares-to-the-company-6308404)
- 2025-12-09 15:11 UTC [SEC Form 4] [Chief Technology Officer Gangloff Scott A. returned 26,351 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-technology-officer-gangloff-scott-a-returned-26351-shares-to-6308399)
- 2025-12-09 15:11 UTC [SEC Form 4] [Chief Financial Officer White William Richard returned 57,752 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-white-william-richard-returned-57752-shares-to-6308398)
- 2025-12-09 15:06 UTC [SEC Form 4] [Chief Development Officer Yale Catriona returned 74,800 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-development-officer-yale-catriona-returned-74800-shares-to-the-6308393)
- 2025-12-09 15:06 UTC [SEC Form 4] [Director Henderson Jane returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-henderson-jane-returned-9398-shares-to-the-company-closing-6308392)
- 2025-12-09 15:06 UTC [SEC Form 4] [Officer Lamy Patrick returned 29,891 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/officer-lamy-patrick-returned-29891-shares-to-the-company-closing-6308391)
- 2025-12-09 15:03 UTC [SEC Form 4] [Chief Operating Officer Young Jonathan returned 260,189 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-young-jonathan-returned-260189-shares-to-the-6308389)
- 2025-12-09 14:36 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-akero-therapeutics-inc-6308365)
- 2025-12-09 14:36 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-akero-therapeutics-inc-6308364)
- 2025-12-09 14:36 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-akero-therapeutics-inc-6308363)
- 2025-12-09 14:36 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-akero-therapeutics-inc-6308362)
- 2025-12-09 14:36 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-akero-therapeutics-inc-6308361)
- 2025-12-09 14:36 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-akero-therapeutics-inc-6308360)
- 2025-12-09 14:25 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-akero-therapeutics-inc-6308346)
- 2025-12-09 14:24 UTC [SEC Form POSASR filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-akero-therapeutics-inc-6308341)
- 2025-12-09 14:12 UTC [SEC Form 8-K] [Akero Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/akero-therapeutics-inc-filed-sec-form-8-k-termination-of-a-6308320)
- 2025-12-09 13:51 UTC [Novo Nordisk has completed its acquisition of Akero Therapeutics](https://www.quantisnow.com/insight/novo-nordisk-has-completed-its-acquisition-of-akero-therapeutics-6308218)
- 2025-12-03 15:42 UTC [SEC Form 8-K] [Akero Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/akero-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6301124)
- 2025-11-28 11:03 UTC [SEC Form 4] [Chief Scientific Officer Rolph Timothy exercised 152,678 shares at a strike of $4.09, increasing direct ownership by 118% to 282,149 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-rolph-timothy-exercised-152678-shares-at-a-6295931)
- 2025-11-26 21:03 UTC [SEC Form 4] [Chief Operating Officer Young Jonathan gifted 9,259 shares and exercised 12,550 shares at a strike of $23.13, increasing direct ownership by 2% to 200,189 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-young-jonathan-gifted-9259-shares-and-exercised-6295005)
- 2025-11-24 20:48 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-akero-therapeutics-inc-6291651)
- 2025-11-21 23:25 UTC [SEC Form 4] [President and CEO Cheng Andrew gifted 74,538 shares, decreasing direct ownership by 15% to 436,837 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-cheng-andrew-gifted-74538-shares-decreasing-direct-6290808)
- 2025-11-20 01:04 UTC [SEC Form 4] [Chief Scientific Officer Rolph Timothy gifted 37,100 shares, decreasing direct ownership by 22% to 129,471 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-rolph-timothy-gifted-37100-shares-decreasing-direct-6287715)
- 2025-11-14 17:19 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-akero-therapeutics-inc-6279781)
- 2025-11-14 17:07 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-akero-therapeutics-inc-6279689)
- 2025-11-14 01:03 UTC [SEC Form 4] [President and CEO Cheng Andrew gifted 14,739 shares, decreasing direct ownership by 3% to 511,375 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-cheng-andrew-gifted-14739-shares-decreasing-direct-6278614)
- 2025-11-12 14:33 UTC [SEC Form SCHEDULE 13G filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-akero-therapeutics-inc-6273479)
- 2025-11-07 22:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-akero-therapeutics-inc-6268792)
- 2025-11-07 18:43 UTC [SEC Form DEFM14A] [SEC Form DEFM14A filed by Akero Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defm14a-filed-by-akero-therapeutics-inc-6267869)
- 2025-11-07 12:00 UTC [Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025](https://www.quantisnow.com/insight/akero-therapeutics-presents-new-analyses-from-phase-2b-symmetry-and-6267112)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AKRO
- Earnings history: https://www.quantisnow.com/earnings/AKRO
- Dividend history: https://www.quantisnow.com/dividends/AKRO
- Insider transactions: https://www.quantisnow.com/insiders/AKRO
- Options chain: https://www.quantisnow.com/options/AKRO
- SEC 8-K filings only: https://www.quantisnow.com/company/AKRO/8-k
- RSS and alerts for AKRO: https://www.quantisnow.com/docs/rss-feeds.md